Mecobalamin – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:55 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Mecobalamin – CRI Report https://www.cri-report.com 32 32 Research Report on China’s Mecobalamin Market, 2021-2025 https://www.cri-report.com/research-report-on-chinas-mecobalamin-market-2021-2025/ Mon, 19 Jul 2021 02:43:40 +0000 https://www.cri-report.com/?post_type=product&p=13244 Due to the impact of the new covid-19 pandemic on the overall treatment services of hospitals, the sales of Mecobalamin in the Chinese Market declined to CNY529 million in 2020, with a CAGR of -3.44% from 2016 to 2020.

The post Research Report on China’s Mecobalamin Market, 2021-2025 first appeared on CRI Report.

]]> Mecobalamin is an endogenous coenzyme B12, which has a good effect on neuronal conduction compared with other types of vitamin B12, and can promote nucleic acid-protein-lipid metabolism through methyl conversion reaction. It is mainly used in clinical practice for peripheral neuropathy and megaloblastic anemia caused by vitamin B12 deficiency. In addition, Mecobalamin has been widely used in clinical practice to promote nerve anastomosis in reinserted fingers, promote sensory recovery, and improve neurological symptoms caused by disc herniation, sciatica, facial palsy, herpes zoster, etc.

Eisai’s Mecobalamin, whose trade name is Methycocal, was approved to enter the Chinese market in 1998, followed by other companies’ generic drugs. According to CRI’s market research, by 2020, there will be several suppliers in the mecobalamin market in China, with North China Pharmaceutical Company Limited as the main supplier.

According to CRI’s research data, the sales of Mecobalamin in the Chinese Market are relatively stable from 2016 to 2019. Due to the impact of the new crown epidemic on the overall treatment services of hospitals, the sales of Mecobalamin in the Chinese Market declined to CNY529 million in 2020, with a CAGR of -3.44% from 2016 to 2020.

CRI expects the sales volume of Mecobalamin in the Chinese Market to recover in 2021-2025 with the effective mitigation of the New Crown epidemic. Meanwhile, Eisai’s Mecobalamin has been selected by the Chinese government for the third batch of volume procurement, and the sales volume is expected to rise significantly. With the improvement and popularization of medical services in China, the demand for Mecobalamin will continue to increase, and the sales volume of Mecobalamin in China will have some upside.

 

Key Points：

  • -Impact of COVID-19 on China’s Mecobalamin Market
  • -Development Environment of Mecobalamin in China
  • -Sales Volume of Mecobalamin in China
  • -Sales Volume and Sales Value of Mecobalamin in Different Regions of China
  • -Major Mecobalamin Manufacturers in China and Their Market Shares
  • -Market Prices of Mecobalamin in China
  • -Major Mecobalamin Manufacturers in China
  • -Prospect on China’s Mecobalamin Market, 2021-2025

The post Research Report on China’s Mecobalamin Market, 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Mecobalamin Market, 2018-2022 https://www.cri-report.com/investigation-report-on-chinas-mecobalamin-market-2018-2022/ Thu, 13 Dec 2018 02:22:22 +0000 https://www.cri-report.com/product/import-placeholder-for-1812361/ Description Peripheral neuropathy is a syndrome caused by many factors. Mecobalamin is a peripheral nerve repair agent. Mecobalamin tablets are used to treat peripheral neuropathy and diseases caused by vitamin B12 deficiency by repairing damaged nerves, relieving pain and numbness, and alleviating sensory disturbances and movement abnormalities. Mecobalamin injection can be used to treat megaloblastic anemia. Developed by Eisai Co., Ltd., Mecobalamin (trade name: Methycobal) was launched in Japan in the mid-1980s and introduced to China in 1996. Since 2003, several Chinese pharmaceutical companies have launched generic Mecobalamin products. Mecobalamin…

The post Investigation Report on China’s Mecobalamin Market, 2018-2022 first appeared on CRI Report.

]]> Description
Peripheral neuropathy is a syndrome caused by many factors.
Mecobalamin is a peripheral nerve repair agent. Mecobalamin tablets are used to treat peripheral neuropathy and diseases caused by vitamin B12 deficiency by repairing damaged nerves, relieving pain and numbness, and alleviating sensory disturbances and movement abnormalities. Mecobalamin injection can be used to treat megaloblastic anemia.
Developed by Eisai Co., Ltd., Mecobalamin (trade name: Methycobal) was launched in Japan in the mid-1980s and introduced to China in 1996. Since 2003, several Chinese pharmaceutical companies have launched generic Mecobalamin products. Mecobalamin has been developing rapidly since it entered China, with its annual sales value increasing from less than CNY 200 million in 2005 to about CNY 609 million in 2017. There is huge demand for Mecobalamin in China. China’s Mecobalamin market is dominated by Eisai China Inc., Eisai Co., Ltd., Jiangsu Sihuan Biopharmaceutical Co., Ltd., Nanjing Hailing Pharmaceutical Co., Ltd., North China Pharmaceutical Company Ltd., etc. In 2017, the market share by sales value of Eisai Co., Ltd. and its subsidiary Eisai China Inc. totaled about 70%.
It is expected that as the lifestyle changes and the population ages, and the incidences of peripheral neuropathy and megaloblastic anemia gradually increases, Mecobalamin will still have some growth potential in China.

Topics Covered:
– Indications for Mecobalamin
– Sales of Mecobalamin in China
– Competition on China’s Mecobalamin market
– Major Mecobalamin manufacturers in China
– Prices of Mecobalamin in China from 2017 to 2018
– Major factors influencing the development of China’s Mecobalamin market
– Prospect of China’s Mecobalamin market from 2018 to 2022

The post Investigation Report on China’s Mecobalamin Market, 2018-2022 first appeared on CRI Report.

]]>